Valuation : Lead Data Inc.

Market Cap 54Cr 1.71Cr 1.47Cr 1.39Cr 1.26Cr 2.36Cr 162.71Cr 2.37Cr 16Cr 6.35Cr 83Cr 6.42Cr 6.28Cr 262.6Cr P/E 2024
-3.97x
P/E 2025 -12.2x
Enterprise Value 57Cr 1.8Cr 1.55Cr 1.46Cr 1.33Cr 2.49Cr 171.5Cr 2.5Cr 17Cr 6.69Cr 87Cr 6.77Cr 6.62Cr 276.8Cr EV / Sales 2024
33.7x
EV / Sales 2025 5.13x
Free-Float
64.34%
Yield 2024 *
-
Yield 2025 -
3 years 2.27
Extreme 2.27
6.48
5 years 2.27
Extreme 2.27
6.48
10 years 1.89
Extreme 1.89
8.54
Manager TitleAgeSince
Chief Executive Officer - 17/08/2022
Director of Finance/CFO - 10/06/2022
Corporate Officer/Principal - 10/06/2022
Director TitleAgeSince
Director/Board Member - 10/06/2019
Chairman - 17/08/2022
Director/Board Member - 10/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-9.85%-.--%-.--%+13.33% 1.71Cr
-0.50%-2.06%+30.86%+19.18% 990.31Cr
-0.08%-1.37%+4.06%+0.21% 140.15Cr
-3.44%-4.60% - - 133.32Cr
-1.48%-3.51%-5.92%-15.52% 114.14Cr
-0.22%+7.92%+98.66%+61.43% 79Cr
-1.13%-1.47%-23.31%-53.74% 61Cr
-0.14%-0.14%-15.67%-11.65% 42Cr
0.00%-3.48%+89.61%+143.27% 42Cr
-0.24%-1.26%-6.44%+14.05% 22Cr
Average -1.71%-2.19%+19.10%+18.95% 162.71Cr
Weighted average by Cap. -0.77%+0.13%+26.65%+16.52%

Financials

2024 2025
Net sales 1.55Cr 5L 4L 4L 4L 7L 4.67Cr 7L 47.14L 18.22L 2.38Cr 18.43L 18.03L 7.54Cr 11Cr 35.13L 30.23L 28.46L 25.94L 48.53L 33Cr 48.72L 3.37Cr 1.3Cr 17Cr 1.32Cr 1.29Cr 54Cr
Net income -13Cr -42.46L -36.54L -34.4L -31.35L -58.65L -40Cr -58.89L -4.08Cr -1.58Cr -21Cr -1.59Cr -1.56Cr -65Cr -4.4Cr -13.97L -12.02L -11.32L -10.31L -19.3L -13Cr -19.38L -1.34Cr -51.85L -6.77Cr -52.46L -51.32L -21Cr
Net Debt -1.7Cr -5L -5L -4L -4L -7L -5.12Cr -7L -51.67L -19.97L -2.61Cr -20.2L -19.77L -8.26Cr 2.91Cr 9L 8L 7L 7L 12.77L 8.79Cr 12.82L 88.75L 34.3L 4.48Cr 34.7L 33.95L 14Cr
Logo Lead Data Inc.
Lead Data Inc is a Taiwan-based company principally engaged in the trading business of medical equipment. The Company’s main products include continuous positive airway pressures (CPAP), hearing aids, oxygen concentrators, oxygen concentrators and rapid screening reagents for novel coronavirus pneumonia (COVID-19). CPAP can treat obstructive sleep apnea. It also has great benefits in improving sleep quality and solving snoring problems. The Company mainly operates in Taiwan and mainland China.
Employees
-
  1. Stock Market
  2. Stocks
  3. 2443 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!